…
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
AnGes Inc is a Japan-based biotechnology company developing gene therapies and DNA-based therapeutics, including plasmid DNA vaccines and angiogenic gene treatments. Long-term growth may be supported by clinical progress and regulatory approvals across its development programs, licensing or partnerships that enable commercialization, and demand from aging populations with unmet vascular and infectious disease needs, which may appeal to investors seeking exposure to genetic-therapy platforms.
Principal investment risks are high clinical and regulatory failure probability, limited commercial revenue necessitating additional financing, and competitive or technological shifts that could erode program value.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -5236.58M | -27643.67M | -7471.41M | - | -13735.29M |
| Net income | -5123.27M | -28128.98M | -7437.61M | - | -13675.59M |
| Selling general administrative | 1912.60M | 5573.76M | 5814.01M | - | 4855.70M |
| Gross profit | 320.38M | 247.70M | 19.45M | - | 7.43M |
| Reconciled depreciation | 53.84M | 3371.64M | 3109.06M | - | 2426.08M |
| Ebit | - | - | - | -16316.00M | -15632.00M |
| Ebitda | - | - | - | - | -13206.00M |
| Operating income | -5145.39M | -9109.44M | -11967.50M | - | -15632.08M |
| Other operating expenses | - | - | - | - | 256.00M |
| Interest expense | - | - | - | - | 0.00M |
| Tax provision | -113.31M | 485.32M | -33.81M | - | -59.71M |
| Interest income | 14.86M | 4.45M | 8.41M | - | 0.57M |
| Net interest income | -27.48M | -53.13M | -11.80M | - | -97.37M |
| Income tax expense | - | - | - | -2.00M | -59.00M |
| Total revenue | 874.12M | 643.64M | 152.99M | - | 64.15M |
| Total operating expenses | 6019.51M | 9753.08M | 12120.49M | - | 15696.23M |
| Cost of revenue | 553.74M | 395.94M | 133.54M | - | 56.72M |
| Net income from continuing ops | -5123.27M | -28128.98M | -7437.61M | - | -13675.59M |
| Net income applicable to common shares | - | - | - | -14714.00M | -13675.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 5405.98M | 4668.60M | 28892.54M | 38820.71M | 45455.75M |
| Intangible assets | 7.63M | 9.66M | - | - | - |
| Other current assets | 28.50M | 9.91M | 32.60M | 361.00M | 1786.00M |
| Total liab | 2329.90M | 2512.01M | 2789.37M | 8395.31M | 6821.01M |
| Total stockholder equity | 3076.08M | 2156.59M | 26103.17M | 30425.41M | 38634.74M |
| Other current liab | 13.11M | 14.18M | 15.44M | 6520.00M | 5933.00M |
| Common stock | - | - | - | 35146.00M | 33359.00M |
| Capital stock | 40228.66M | 37255.89M | 35053.89M | 35146.37M | 33359.57M |
| Retained earnings | -51637.86M | -46514.59M | -18385.61M | -27150.00M | -12435.00M |
| Other liab | - | - | - | 80.00M | 89.00M |
| Good will | - | 0.00M | 21746.09M | 23254.47M | 22675.74M |
| Other assets | - | - | - | 160.00M | 111.00M |
| Cash | 1882.01M | 1707.76M | 4160.42M | 11035.10M | 17899.34M |
| Total current liabilities | 2243.47M | 2313.28M | 2493.16M | 7323.00M | 6733.00M |
| Other stockholder equity | - | - | - | 4960.00M | 2029.00M |
| Property plant equipment | - | - | - | 1410.00M | 193.00M |
| Total current assets | 4386.54M | 3542.61M | 5921.28M | 12896.00M | 21426.00M |
| Net tangible assets | - | - | - | 7169.00M | 15958.00M |
| Net receivables | 121.62M | 85.23M | 26.53M | 401.00M | 429.00M |
| Inventory | 1746.52M | 1429.18M | 1566.14M | 1008.00M | 1223.00M |
| Accounts payable | 542.96M | 307.94M | 426.45M | 553.00M | 720.00M |
| Non currrent assets other | 2.88M | 0.95M | 1.51M | 81.25M | 73.48M |
| Non current assets total | 1019.44M | 1125.99M | 22971.26M | 25924.25M | 24029.60M |
| Capital lease obligations | 54.37M | 272.45M | 362.68M | 1155.71M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -56.95M | -356.65M | -74.00M | -74.00M |
| Change to liabilities | - | - | - | -317.00M | -453.00M |
| Total cashflows from investing activities | - | - | - | -97.00M | -154.00M |
| Net borrowings | 0.00M | 1300.00M | 0.00M | - | - |
| Total cash from financing activities | - | - | - | 3572.00M | 17378.00M |
| Change to operating activities | - | - | - | 641.00M | 261.00M |
| Net income | -5123.27M | -28128.00M | 1067.00M | -14714.00M | -13675.00M |
| Change in cash | 168.40M | -2464.49M | -6877.52M | -6866.00M | 6298.00M |
| Begin period cash flow | 1627.67M | 4092.16M | 10969.68M | 17835.70M | 11537.03M |
| End period cash flow | 1796.07M | 1627.67M | 4092.16M | - | 17835.70M |
| Total cash from operating activities | -5750.37M | -6612.88M | -8745.76M | -11214.00M | -11380.00M |
| Issuance of capital stock | 5870.21M | 3008.40M | 2033.14M | - | 17280.79M |
| Depreciation | 53.84M | 3371.64M | 3109.06M | 2901.00M | 2425.00M |
| Other cashflows from investing activities | - | - | - | -4.00M | -74.00M |
| Change to inventory | -317.33M | 136.95M | -557.69M | 215.00M | -32.00M |
| Change to account receivables | - | - | - | - | 2.00M |
| Sale purchase of stock | 0.00M | -0.01M | 0.00M | - | -0.32M |
| Change to netincome | - | - | - | 62.00M | 152.00M |
| Capital expenditures | 14.32M | 77.45M | 89.33M | 19.00M | 80.00M |
| Change in working capital | -622.53M | -374.53M | -5106.12M | - | 194.05M |
| Stock based compensation | 0.35M | 5.19M | 42.43M | - | 60.65M |
| Other non cash items | 22.31M | 46.90M | 8.71M | - | 62.58M |
| Free cash flow | -5764.69M | -6690.33M | -8835.09M | - | -11478.14M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AMGXF AnGes Inc |
- -% |
0.36 | - | - | 0.16 | 0.73 | 38.42 | -0.01 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
| Name | Title | Year Born |
|---|---|---|
| Dr. Ei Yamada M.D., Ph.D. | CEO, Pres & Representative Director | 1950 |
| Naoya Sato | Director of Corp. Devel. & Director | NA |
| Dr. Ei Yamada M.D., Ph.D. | CEO, President & Representative Director | 1950 |
| Mr. Naoya Sato | Director of Corporate Development & Director | 1960 |
| Yuka Murakami | Accounting Department Manager | NA |
| Mr. Naoya Sato | Director of Administration & Director | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.